Recombinetics

Recombinetics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $54.5M

Overview

Recombinetics is a pioneering US-based biotechnology company specializing in gene editing for large animals, primarily swine and cattle. It operates a dual-market strategy, providing custom gene-edited swine models for preclinical biomedical research and developing agriculturally beneficial traits like disease resistance and heat tolerance in livestock. The company boasts a strong intellectual property portfolio, a history of industry 'firsts,' and is positioning itself for rapid growth in both the biomedical and agricultural sectors.

OncologyGenetic DisordersRegenerative Medicine

Technology Platform

Integrated platform for large animal gene editing, combining CRISPR/TALENs expertise, stem cell biology, serial multiplex editing, bioinformatics, and AI to create custom swine models for research and traits for livestock.

Funding History

3
Total raised:$54.5M
Grant$500K
Series B$20M
Series A$34M

Opportunities

The massive growth in cell and gene therapy trials creates a urgent need for better preclinical models, positioning Recombinetics' swine models as a potential industry standard.
In agriculture, global pressure for sustainable and efficient protein production drives demand for genetically improved livestock with traits for health, welfare, and resilience.

Risk Factors

The company faces significant regulatory uncertainty and varying global policies regarding gene-edited animals.
Market adoption risks include slow uptake by pharmaceutical researchers accustomed to rodent models and potential consumer hesitancy towards gene-edited food products.

Competitive Landscape

In biomedical models, Recombinetics competes with other specialized CROs and academic centers creating animal models, but its focus on swine and gene editing is a key differentiator. In agricultural genetics, it competes with traditional animal breeding companies and larger agribiotech firms like Genus PLC, but its precision breeding via gene editing offers a speed and specificity advantage.